MedTrace Logo

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

NCT00993239 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-03-03

No results posted yet for this study

Summary

A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).

Conditions

Interventions

DRUG

Birinapant (TL32711)

30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated

Sponsors & Collaborators

  • TetraLogic Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ravi Amaravadi, MD · University of Pennsylvania, Abramson Cancer Center

  • Lainie P Martin, MD · Fox Chase Cancer Center

  • Alex Adjei, MD, PhD · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-08-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00993239 on ClinicalTrials.gov